Literature DB >> 25734636

CD30-targeting immunoconjugates and bystander effects.

Shigeo Masuda1, Shigeru Miyagawa1, Nagako Sougawa1, Yoshiki Sawa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25734636     DOI： 10.1038/nrclinonc.2014.159-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

Authors:  Django Sussman; Leia M Smith; Martha E Anderson; Steve Duniho; Joshua H Hunter; Heather Kostner; Jamie B Miyamoto; Albina Nesterova; Lori Westendorf; Heather A Van Epps; Nancy Whiting; Dennis R Benjamin
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

Review 3.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

4.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

5.  Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Authors:  Sven Golfier; Charlotte Kopitz; Antje Kahnert; Iring Heisler; Christoph A Schatz; Beatrix Stelte-Ludwig; Anke Mayer-Bartschmid; Kerstin Unterschemmann; Sandra Bruder; Lars Linden; Axel Harrenga; Peter Hauff; Frank-Detlef Scholle; Beate Müller-Tiemann; Bertolt Kreft; Karl Ziegelbauer
Journal:  Mol Cancer Ther       Date:  2014-04-08       Impact factor: 6.261

6.  Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

Authors:  Vincent A DiPippo; William C Olson; Holly M Nguyen; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

7.  Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Authors:  Nicole M Okeley; Jamie B Miyamoto; Xinqun Zhang; Russell J Sanderson; Dennis R Benjamin; Eric L Sievers; Peter D Senter; Stephen C Alley
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

8.  A CXCR4-targeted site-specific antibody-drug conjugate.

Authors:  Sumith A Kularatne; Vishal Deshmukh; Jennifer Ma; Virginie Tardif; Reyna K V Lim; Holly M Pugh; Ying Sun; Anthony Manibusan; Aaron J Sellers; Richard S Barnett; Shailaja Srinagesh; Jane S Forsyth; Wolf Hassenpflug; Feng Tian; Tsotne Javahishvili; Brunhilde Felding-Habermann; Brian R Lawson; Stephanie A Kazane; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2014-09-11       Impact factor: 15.336

9.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Authors:  Steven M Horwitz; Ranjana H Advani; Nancy L Bartlett; Eric D Jacobsen; Jeff P Sharman; Owen A O'Connor; Tanya Siddiqi; Dana A Kennedy; Yasuhiro Oki
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

10.  The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Authors:  K A Beckwith; F W Frissora; M R Stefanovski; W H Towns; C Cheney; X Mo; J Deckert; C M Croce; J M Flynn; L A Andritsos; J A Jones; K J Maddocks; G Lozanski; J C Byrd; N Muthusamy
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528
  10 in total
  5 in total

1.  Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.

Authors:  Aman P Singh; Sharad Sharma; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-26       Impact factor: 2.745

2.  Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.

Authors:  Ryan Ashkar; Darren R Feldman; Nabil Adra; Mohammad Abu Zaid; Samuel A Funt; Sandra K Althouse; Susan M Perkins; Christin I Snow; Kayla M Lazzara; Lina M Sego; David I Quinn; Nasser H Hanna; Lawrence H Einhorn; Costantine Albany
Journal:  Invest New Drugs       Date:  2021-05-24       Impact factor: 3.651

Review 3.  Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Authors:  Alexander H Staudacher; Michael P Brown
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

Review 4.  Fate of Antibody-Drug Conjugates in Cancer Cells.

Authors:  Cécile Chalouni; Sophia Doll
Journal:  J Exp Clin Cancer Res       Date:  2018-02-06

5.  Atorvastatin Inhibits the HIF1α-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells.

Authors:  Yoshiki Nakashima; Chika Miyagi-Shiohira; Hirofumi Noguchi; Takeshi Omasa
Journal:  Mol Ther       Date:  2018-06-19       Impact factor: 11.454
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.